25 September 2015 - The World Health Organization identified more than 14,000 disease, disorders, and ailments in 2011, but none continues to garner more attention from drugmakers than cancer.

In 2014, global cancer drug sales hit $100 billion for the first time, according to IMS Health, with forecasts calling for global sales growth of another 17% to 47% by 2018. Oncology is a fast-growing space, and drug developers want their share of the pie.

Even more importantly, there's still plenty of research left to be done to cure cancer. Don't get me wrong, we've seen marked survival improvements in breast cancer and prostate cancer, the two most-common cancer types, according to data from the American Cancer Society. However, new therapies are still needed in dozens of cancer types that have only seen marginal improvements over the last four decades.

The potentially good news for patients is that the Food and Drug Administration could approve as many as three cancer therapies in October, providing potentially new options to certain cancer patients. Let's have a brief look at these three upcoming FDA decisions and dissect the likelihood of an approval.

For more details, go to: http://www.fool.com/investing/general/2015/09/24/will-the-fda-approve-all-3-of-these-cancer-drugs-i.aspx